poisar

Stocks · News reference

HC Wainwright & Co. Reiterates Buy on NovaBridge Biosciences, Maintains $9 Price Target

Aug 20, 2026, 4:38 PMBenzinga Newsdesk

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates NovaBridge Biosciences (NASDAQ:NBP) with a Buy and maintains $9 price target.

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

NBP
Source
benzinga
Observed
Aug 20, 2026, 4:38 PM
Checked
Aug 20, 2026, 4:38 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Jul 24, 2026, 9:00 PMNovabridge Biosciences

    NovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026

    NovaBridge Biosciences announced its annual general meeting of shareholders will be held on September 8, 2026, at its Shanghai office. The company, a clinical-stage biopharmaceutical firm, is advancing innovative medicines including givastomig for gastric cancer and VIS-101 for retinal vascular diseases. Shareholders of record as of July 27, 2026, are entitled to attend and vote.

    Read original at globenewswire-inc
    NBP